LIVE WEBINAR
Harnessing GLP-1 and Amylin Power for Obesity Care with Reliable Preclinical In Vivo Models
GLP-1 and amylin are reshaping obesity drug development with their synergistic weight loss effects. Join our webinar to explore how Cyagen’s validated in vivo models and pharmacology services can support your preclinical research and fast-track anti-obesity drug discovery.
DATE
August 8, 2025 | 10:00 - 11:00 AM (PDT)
LOCATION
Online | YouTube
Webinar Summary
Obesity, characterized by excessive fat accumulation, affects over one-third of
the global population and is increasingly recognized as a chronic disease requiring long-term management.
Amylin, a peptide hormone co-secreted with insulin, shows promise in regulating satiety and energy balance.
It targets brain regions for appetite and reward, delays gastric emptying, and inhibits postprandial
glucagon secretion, making it a potent metabolic modulator.
When combined with GLP-1 receptor agonists, amylin analogues offer synergistic
weight loss potential. The success of GLP-1 receptor agonists like semaglutide and tirzepatide highlights
the immense potential of these pathways for obesity treatment. As drug developers explore combination
therapies, GLP-1 and amylin offer a compelling avenue for next-generation anti-obesity drugs. Cyagen
provides comprehensive, researcher-validated CRO Solutions for Metabolic & Cardiovascular Diseases , with
specialized models like db/db and ob/ob (C57BL/6JCya strain) designed for obesity research. This webinar
will demonstrate how our advanced preclinical models and pharmacology services can accelerate your drug
development programs, providing crucial insights and reliable data for your anti-obesity pipeline.
Topic Covered
- Overview of GLP-1 and Amylin Physiology
- In-depth Overview of GLP-1 and Amylin Physiology for Drug Development
- Introduction to DIO as a translationally relevant obesity model
- Pharmacodynamic Validation Results
Who Should Attend
- Pharmaceutical and biotech companies (R&D or preclinical teams)
- Academic institutions and research hospitals
- Early-stage biotech startups focused on metabolic or hormonal therapeutics
-
Researchers and professionals with focus on:- Obesity and metabolic disease drug development- Hormone signaling pathways (GLP-1, Amylin, insulin)- Preclinical pharmacology and animal model evaluation
Attend this Webinar to:
- Gain insights into the mechanisms of action of GLP-1 and Amylin in obesity treatment
- Discover the latest preclinical animal models for anti-obesity drug evaluation, including DIO and hormone-based models
- Understand how validated in vivo pharmacology platforms can streamline and accelerate the drug discovery process
- Learn how Cyagen’s CRO services and ready-to-use small animal models can support and advance your pipeline development
Webinar Presenter
{{value.name}}
{{value.title}}
{{value.company}}
{{value.descript}}
Discover Our Solutions
{{ value.label }}
{{ value.name }}
Explore
Request Information About This Webinar
Whether you're joining live or catching up later, fill out the form to receive materials or updates related to this webinar.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.